Nov 30 2024

Colorado Marijuana Sales Top $110 Million in September, Bringing Year-to-Date Total to Above $1 Billion

Colorado’s legal marijuana market has generated over $1 billion in revenue so far in 2024.

There was $112,429,698 worth of legal marijuana and marijuana products sold in September in Colorado, bringing the year-to-date total to $1,060,994,048. This is according to data released today by the Colorado Department of Revenue

Of the $112.4 million in marijuana sold legally in September, $100,516,124 was purchased for recreational use, whereas medical marijuana patients purchased $11,913,574 in product. September sales resulted in $20,927,011 in tax revenue.
Continue reading

Nov 29 2024

Massachusetts Marijuana Sales Surpass $7 Billion as Prices Hit Record Low

Despite prices reaching an all-time low, there was an uptick in marijuana sales from September to October, with all-time sales passing the $7 billion mark.

In October, licensed marijuana stores in Massachusetts sold $138.8 million in recreational marijuana and $14.8 million in medical marijuana, totaling $153.6 million. Combined with $119 million in November sales through the 24th, the year-to-date total is now $1.5 billion, with an all-time total of $7.01 billion, according to data released today by the Massachusetts Cannabis Control Commission (CCC).

In October, average marijuana prices reached an all-time low of $4.78 per gram and $135.53 per ounce. Only Oregon has cheaper legal cannabis prices.
Continue reading

Nov 29 2024

Arapahoe County, Colorado Commission Unanimously Approves Psilocybin Business Regulations

Arapahoe County commissioners have unanimously approved a comprehensive set of regulations governing psilocybin businesses as Colorado prepares to begin licensing these operations in January 2025.

The decision follows the voter-approved Proposition 122, which decriminalized the use, possession, and cultivation of psilocybin mushrooms, making Colorado the second state to take such a step.

Under Proposition 122, individuals aged 21 and older can legally use certain plants and fungi for personal and therapeutic purposes. Unlike marijuana legalization under Amendment 64, which allowed local jurisdictions to ban retail marijuana businesses, Proposition 122 prohibits local governments from banning natural medicine businesses. However, counties like Arapahoe retain the authority to regulate these businesses’ time, manner, and location within the bounds of state law.
Continue reading

Nov 29 2024

Marijuana Use Associated with Large Reduction in Opioid Prescriptions Among Chronic Pain Patients in Utah, Finds Study

According to the results of a newly published study conducted in Utah, cannabis has the potential to to serve as an alternative to opioids for chronic pain management.

For the study, published on Utah.gov, researchers analyzed the impact of medical cannabis on opioid prescription rates, focusing on 186 patients with chronic pain diagnoses. The study utilized patient data from Dragonfly Wellness dispensaries and electronic health records, revealing a compelling trend of reduced opioid use following cannabis initiation.

The study found that 84.4% of participants experienced a decrease in their opioid prescriptions after beginning cannabis treatment. On average, opioid consumption, measured in Morphine Milligram Equivalents (MME) per month, dropped by 53.1%. This equated to a reduction from 3,832 MME/month before cannabis use to 1,798 MME/month afterward. Patients using cannabis products with a THC:CBD ratio of 1:0 showed the most significant reductions.
Continue reading

Nov 29 2024

Study: Fluorinated Cannabinoids Show Promising Therapeutic Potential

A new study published in the journal Pharmacological Reports highlights the therapeutic potential of four newly developed fluorinated cannabinoids.

Conducted by researchers from Oklahoma State University Center for Health Sciences and Universität Regensburg in Germany, the study explores the biological activity of these compounds, particularly their anti-inflammatory properties.

“Phytochemicals derived from the plant Cannabis sativa hold promise in terms of medicinal value”, states the study. “Cannabinoids such as Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) are arguably the best characterized and known to possess wide-ranging therapeutic benefits. The mechanism of action for these therapeutic effects remains to be fully elucidated, however, the anti-inflammatory actions are of particular interest.”
Continue reading

Nov 29 2024

Idaho Secretary of State Approves 2026 Marijuana Decriminalization Initiative for Signature Collection

Idaho has advanced a proposed measure to decriminalize marijuana by approving its title and summary, clearing the way for signature collection.

The measure, proposed by Kind Idaho, would decriminalize personal use and cultivation of marijuana for adults aged 21 and older if approved by voters in 2026. The secretary of state has  authorized the petition for circulation, allowing organizers to begin gathering the 70,725 signatures needed to place it on the ballot. The official “short ballot title” for the proposal calls it a “Measure decriminalizing the possession, production, and cultivation of marijuana and marijuana-infused products for personal use by persons 21 or older.”

The measure would allow for the possession of up to one ounce of marijuana flower or 1,000 milligrams of THC in products like oils, tinctures, and edibles. It also allows home cultivation of up to 12 plants, with adults able to securely store up to eight ounces of marijuana harvested from those plants at home or on private property, provided it remains inaccessible to minors. Consumption in public or open settings would be prohibited.
Continue reading

Nov 29 2024

Study: CBD May Protect Against Chemotherapy-Induced Liver Damage

Researchers from Suleyman Demirel University and Alanya Alaaddin Keykubat University in Turkey have found that cannabidiol (CBD) may alleviate liver damage caused by methotrexate (MTX), a commonly used chemotherapy drug.

The study, published in Drug and Chemical Toxicology, highlights CBD’s potential as a protective agent against MTX-induced hepatotoxicity by targeting oxidative stress and inflammation.

The research involved 32 female Wistar Albino rats, divided into four groups: a control group, an MTX-only group, an MTX+CBD group, and a CBD-only group. The MTX+CBD group received a single dose of MTX (20 mg/kg) followed by daily CBD injections (5 mg/kg) for seven days. Researchers assessed oxidative stress markers, liver enzyme levels, and genetic expressions linked to inflammation and apoptosis.
Continue reading

Nov 29 2024

Study: Medical Marijuana Legalization Shows No Impact on Driving Attitudes in Kentucky and Tennessee

Researchers from Nationwide Children’s Hospital and The Ohio State University have published a new study examining the effects of medical marijuana legalization on attitudes and behaviors toward driving after marijuana use (DAMU) in Kentucky and Tennessee.

Using survey data, researchers applied a novel matched design to infer causal relationships while accounting for observational data challenges such as unequal sampling probabilities and potential confounding.

The study, published in the Biometrical Journal, found no evidence linking medical marijuana legalization to increased tolerance of DAMU. This conclusion remained robust even after sensitivity analyses were conducted to evaluate the impact of unmeasured confounding. Unlike previous studies that suggested minor associations between legalization and self-reported DAMU, this research evaluated both behaviors and attitudes using multiple survey items. The study highlighted regional differences, focusing on Southern and Midwestern states, where self-reported DAMU was rare.
Continue reading

Nov 28 2024

Trump’s Second Term: What It Could Mean for Marijuana Law Reform

The 2024 election resulted in a decisive victory for former President Donald Trump, who has a mixed but clearly evolving history when it comes to marijuana law reform. Here’s what we can expect out of the next four years.

During Trump’s previous term, while he did not support legalizing medical or recreational marijuana or back any specific marijuana legislation, his administration took a hands-off approach to state marijuana laws. His first attorney general, Jeff Sessions, did rescind the Obama-era Cole Memo, which had provided verbal assurances to state-legal marijuana businesses. However, this did not lead to Trump or his administration attempting to supersede state marijuana laws or interfere with legal marijuana programs.

Since leaving office in January 2021, Trump has shown considerable growth on the issue. Earlier this year, Trump endorsed Florida’s Amendment 3, an initiative to legalize recreational marijuana which was strongly opposed by Florida Governor Ron DeSantis. Soon after this endorsement, Trump gave his backing to the federal move to reschedule marijuana, as well as federal marijuana banking legislation.
Continue reading

Nov 28 2024

Ohio: Almost $300 Million in Marijuana Sales Since Launch of Recreational Market on August 7, Over 3.4 Million Transactions

Since the launch of recreational marijuana sales on August 7, Ohio has recorded $283,230,130 in combined sales across both medical and recreational markets, according to the latest data available through November 23.

Recreational marijuana sales have contributed $178,481,465 during this period, while medical marijuana sales totaled $104,748,665, according to data released by the Ohio Department of Commerce’s
Division of Cannabis Control. During this period there were 2,363,214 recreational transactions and 1,109,022 medical transactions.

Prices have seen a significant decline since recreational sales began. The average cost per gram is now $7.68, a noticeable drop from $9.42 in early August. Similarly, the price for one-tenth of an ounce has fallen to $21.72 from $31.06.
Continue reading